Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Indivior PLC
  6. Summary
    INDV   GB00BRS65X63

INDIVIOR PLC

(INDV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
197.1(c) 207.6(c) 209.8(c) 214.2(c) 217 Last
1 458 255 8 017 844 1 903 346 1 397 847 1 667 487 Volume
+0.72% +5.33% +1.06% +2.10% +1.31% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 734 M - -
Net income 2021 151 M - -
Net cash position 2021 729 M - -
P/E ratio 2021 10,9x
Yield 2021 -
Sales 2022 796 M - -
Net income 2022 159 M - -
Net cash position 2022 759 M - -
P/E ratio 2022 9,86x
Yield 2022 -
Capitalization 1 573 M 2 149 M -
EV / Sales 2021 1,15x
EV / Sales 2022 1,02x
Nbr of Employees 788
Free-Float 98,4%
More Financials
Company
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film... 
Sector
Pharmaceuticals
Calendar
11/04Earnings Release
More about the company
Ratings of Indivior PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about INDIVIOR PLC
09/21FTSE 100 recovers 1% on energy, healthcare stock boost; Entain jumps
RE
09/14INDIVIOR : to Participate in Upcoming Healthcare Events During National Recovery Month
PU
09/10INDIVIOR : to Participate in Upcoming Investor Conferences
PU
09/08PRESS RELEASE : Addex to Present at the H.C. Wainwright 23rd Annual Global Investment Conf..
DJ
09/02PRESS RELEASE : Addex to Present at the Swiss Biotech Day
DJ
08/31Today on Wall Street: US tech giants return to top spot
08/31ANALYST RECOMMENDATIONS : AT&T, BancorpSouth Bank, CMO Group, Magnite, Textron...
08/05PRESS RELEASE : Addex Reports 2021 Half Year and -2-
DJ
08/05PRESS RELEASE : Addex Reports 2021 Half Year and Second Quarter Financial Results and Prov..
DJ
08/02PRESS RELEASE : Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Co..
DJ
08/02PRESS RELEASE : Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head ..
DJ
07/30INDIVIOR : Details $100 Million Share Buyback Program
MT
07/29London Indexes Boosted by Positive Welcome to Most Earnings
DJ
07/29INDIVIOR : Reports H1 Swing to Profit, Planned $100 Million Share Buyback
MT
07/29INDIVIOR : Second Quarter and First Half 2021 Financial Results Presentation
PU
More news
News in other languages on INDIVIOR PLC
08/31OPINIONES DE LOS ANALISTAS DEL DÍA : EasyJet, Geberit, Philips, BMW, Infineon, Rovio, Stor..
08/31MADRID STOCK EXCHANGE : Los GAFAM le saludan bien
08/31STOCK MARKET PARIS : Les GAFAM vous saluent bien
08/31AVIS D'ANALYSTES DU JOUR : Safran, Geberit, Philips, BMW, Infineon, Rovi, Stora Enso, Ucar..
08/05Addex voit ses coûts de recherche progresser sur les six premiers mois
More news
Analyst Recommendations on INDIVIOR PLC
More recommendations
Stock Trading Strategies
INDIVIOR PLC - 08/02
Towards the breakout of a major resistance level
BUY
More Stock Trading Analysis
Chart INDIVIOR PLC
Duration : Period :
Indivior PLC Technical Analysis Chart | INDV | GB00BRS65X63 | MarketScreener
Technical analysis trends INDIVIOR PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 2,17 $
Average target price 3,79 $
Spread / Average Target 74,7%
EPS Revisions
Managers and Directors
Mark Crossley Executive Director, CEO & COO
Ryan Preblick Chief Financial Officer & Executive Director
Graham C. Hetherington Chairman
Christian Heidbreder Chief Scientific Officer
Cynthia Cetani Chief Compliance & Integrity Officer
Sector and Competitors